Parkinson’s disease, bipolar disorder, and chronic pain targeted in study
Study aims to support psilocybin as a potential therapeutic for inflammatory disorders
Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies With Its Targeted Protein Degrader SP-3164
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options,
